Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity

Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity

Objectives: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). Methods:We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arabia. Seventy-four eyes of 37 preterm infant...

Full description

Saved in:
Bibliographic Details
Published in:Medical principles and practice Vol. 28; no. 6; pp. 526 - 532
Main Authors: Aldebasi, Tariq, Guma, Muataz A., Bashir, Rabia, Al Saif, Saif, Altwaijri, Waleed A., Al Bekairy, Abdulkareem M.
Format: Journal Article
Language:English
Published: Basel, Switzerland S. Karger AG 01-11-2019
Subjects:
Anesthesia
Birth weight
Blindness
Cryotherapy
Gestational age
Immunotherapy
Intensive care
Monoclonal antibodies
Newborn babies
Original Paper
Premature babies
Premature birth
Retina
Sepsis
Vascular endothelial growth factor
Saudi Arabia
Riyadh Saudi Arabia
Childhood blindness
Anti-VEGF
Retinopathy of prematurity
Vitreoretinal fibrosis
Intravitreal injection
Ranibizumab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). Methods:We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arabia. Seventy-four eyes of 37 preterm infants with ROP stage III with plus disease in zone I, posterior zone II, and aggressive posterior ROP received a single injection of 0.3 mg intravitreal ranibizumab. The favorable outcome measure was complete regression of the disease with normal vascularization of the retina of those infants. Results: The gestational age of the 37 included cases was in the range of 23–28 weeks and their body weight at birth was between 510 and 1,235 g except for one case with 2,550 g under oxygen therapy <7days with severe hypoglycemia. All eyes showed a favorable response in terms of regression of plus disease from the first day after treatment, followed by regression of stage III retinopathy. All patients developed complete vascularization over variable periods of time. Conclusion: One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1011-7571
1423-0151
DOI:10.1159/000500310